98 related articles for article (PubMed ID: 21531212)
1. Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment.
Gullbo J; Fryknäs M; Rickardson L; Darcy P; Hägg M; Wickström M; Hassan S; Westman G; Brnjic S; Nygren P; Linder S; Larsson R
Biochem Pharmacol; 2011 Jul; 82(2):139-47. PubMed ID: 21531212
[TBL] [Abstract][Full Text] [Related]
2. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.
Yip KW; Mao X; Au PY; Hedley DW; Chow S; Dalili S; Mocanu JD; Bastianutto C; Schimmer A; Liu FF
Clin Cancer Res; 2006 Sep; 12(18):5557-69. PubMed ID: 17000693
[TBL] [Abstract][Full Text] [Related]
3. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.
Frankel A; Man S; Elliott P; Adams J; Kerbel RS
Clin Cancer Res; 2000 Sep; 6(9):3719-28. PubMed ID: 10999766
[TBL] [Abstract][Full Text] [Related]
4. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.
Iljin K; Ketola K; Vainio P; Halonen P; Kohonen P; Fey V; Grafström RC; Perälä M; Kallioniemi O
Clin Cancer Res; 2009 Oct; 15(19):6070-8. PubMed ID: 19789329
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
6. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
7. Identification of agents that induce apoptosis of multicellular tumour spheroids: enrichment for mitotic inhibitors with hydrophobic properties.
Fayad W; Rickardson L; Haglund C; Olofsson MH; D'Arcy P; Larsson R; Linder S; Fryknäs M
Chem Biol Drug Des; 2011 Oct; 78(4):547-57. PubMed ID: 21726416
[TBL] [Abstract][Full Text] [Related]
8. Cell-based screening approach for antitumor drug leads which exploits sensitivity differences between normal and cancer cells: identification of two novel cell-cycle inhibitors.
Vassilev LT; Kazmer S; Marks IM; Pezzoni G; Sala F; Mischke SG; Foley L; Berthel SJ
Anticancer Drug Des; 2001 Feb; 16(1):7-17. PubMed ID: 11762646
[TBL] [Abstract][Full Text] [Related]
9. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.
Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A
Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850
[TBL] [Abstract][Full Text] [Related]
10. Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines.
Fernando A; Glaysher S; Conroy M; Pekalski M; Smith J; Knight LA; Di Nicolantonio F; Cree IA
Anticancer Drugs; 2006 Sep; 17(8):913-9. PubMed ID: 16940801
[TBL] [Abstract][Full Text] [Related]
11. Screening for compounds that induce apoptosis of cancer cells grown as multicellular spheroids.
Herrmann R; Fayad W; Schwarz S; Berndtsson M; Linder S
J Biomol Screen; 2008 Jan; 13(1):1-8. PubMed ID: 18040052
[TBL] [Abstract][Full Text] [Related]
12. Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance.
Fryknäs M; Gullbo J; Wang X; Rickardson L; Jarvius M; Wickström M; Hassan S; Andersson C; Gustafsson M; Westman G; Nygren P; Linder S; Larsson R
BMC Cancer; 2013 Aug; 13():374. PubMed ID: 23919498
[TBL] [Abstract][Full Text] [Related]
13. In vitro evaluation of new anticancer drugs, exemplified by vinorelbine, using the fluorometric microculture cytotoxicity assay on human tumor cell lines and patient biopsy cells.
Fridborg H; Nygren P; Dhar S; Csoka K; Kristensen J; Larsson R
J Exp Ther Oncol; 1996 Sep; 1(5):286-95. PubMed ID: 9414416
[TBL] [Abstract][Full Text] [Related]
14. Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma.
Brard L; Granai CO; Swamy N
Gynecol Oncol; 2006 Jan; 100(1):116-27. PubMed ID: 16203029
[TBL] [Abstract][Full Text] [Related]
15. Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer.
Popadiuk CM; Xiong J; Wells MG; Andrews PG; Dankwa K; Hirasawa K; Lake BB; Kao KR
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2216-23. PubMed ID: 16609037
[TBL] [Abstract][Full Text] [Related]
16. A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. I: In vitro studies.
Li L; Zhu Z; Joshi B; Porter AT; Tang DG
Anticancer Res; 1999; 19(1A):51-60. PubMed ID: 10226524
[TBL] [Abstract][Full Text] [Related]
17. Identification of AKN-032, a novel 2-aminopyrazine tyrosine kinase inhibitor, with significant preclinical activity in acute myeloid leukemia.
Eriksson A; Höglund M; Lindhagen E; Aleskog A; Hassan SB; Ekholm C; Fhölenhag K; Jensen AJ; Löthgren A; Scobie M; Larsson R; Parrow V
Biochem Pharmacol; 2010 Nov; 80(10):1507-16. PubMed ID: 20705060
[TBL] [Abstract][Full Text] [Related]
18. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.
Drees M; Dengler WA; Roth T; Labonte H; Mayo J; Malspeis L; Grever M; Sausville EA; Fiebig HH
Clin Cancer Res; 1997 Feb; 3(2):273-9. PubMed ID: 9815683
[TBL] [Abstract][Full Text] [Related]
19. Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells.
Appierto V; Villani MG; Cavadini E; Gariboldi M; De Cecco L; Pierotti MA; Lambert JR; Reid J; Tiberio P; Colombo N; Formelli F
Oncogene; 2007 Jun; 26(27):3952-62. PubMed ID: 17213814
[TBL] [Abstract][Full Text] [Related]
20. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]